The HULIO Bridge Program (“Bridge Program”) provides Hulio® (adalimumab-fkjp) injection (“HULIO”) at no cost for a one time, one month fill, to eligible, insured patients who have been prescribed HULIO for an FDA-approved indication, and whose initial coverage is delayed, including delay as a result of a prior authorization requirement. Patients must be insured and continue to pursue insurance coverage for HULIO with their healthcare provider. Patients must be residents of the United States or its territories. The Bridge Program is not available to patients who are uninsured or where prohibited by law. Neither prescriber nor patient may submit a claim for reimbursement for all, or any part of the benefit received by the patient through this Bridge Program to any public or private third-party payer or any federal or state health care program. Patient must not count free product dispensed pursuant to this Bridge Program towards any out-of-pocket cost obligations, such as Medicare Part D True Out-of-pocket Costs (TrOOP). No purchase necessary. The Bridge Program is not health insurance, nor is participation a guarantee of insurance coverage. Patients have no obligation to continue use of HULIO. Other limitations may apply. Biocon Biologics reserves the right to rescind, revoke, or amend the Bridge Program at any time without notice.

Cookies help us improve your website experience.
By using our website, you agree to our use of cookies.